In Wednesday’s Wall Street session, Cullinan Therapeutics Inc (NASDAQ:CGEM) shares traded at $8.16, down -1.92% from the previous session.
CGEM stock price is now 0.33% away from the 50-day moving average and -29.40% away from the 200-day moving average. The market capitalization of the company currently stands at $481.56M.
On October 24, 2024, UBS recently initiated its ‘Buy’ rating on the stock quoting a target price of $30, while ‘Stifel’ rates the stock as ‘Buy’
In other news, Jones Jeffrey Alan, Chief Medical Officer sold 4,895 shares of the company’s stock on Feb 25 ’25. The stock was sold for $41,754 at an average price of $8.53. Upon completion of the transaction, the Chief Medical Officer now directly owns 174,164 shares in the company, valued at $1.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 25 ’25, President and CEO AHMED NADIM sold 12,529 shares of the business’s stock. A total of $106,872 was realized by selling the stock at an average price of $8.53. This leaves the insider owning 430,621 shares of the company worth $3.51 million. A total of 39.13% of the company’s stock is owned by insiders.
During the past 12 months, Cullinan Therapeutics Inc has had a low of $6.85 and a high of $21.01. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 11.62, and a quick ratio of 11.62.
The company reported revenue of $55.0 million for the quarter, compared to $42.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.93 percent.
